Table 7.
HGBI predicted drug-disease associations (top 10 in ranking list), and the corresponding evidence
| Drug | Disease | Evidence (PMID) | Rank |
|---|---|---|---|
| Lithium | Conduct Disorder | 7491395;7691178;7751258 | 1 |
| Lithium | Depressive Disorder | 27752079;2723135;21252007 | 2 |
| Ertapenem | Pyelonephritis | 22563210 | 3 |
| Moxifloxacin | Pyelonephritis | without evidence | 4 |
| Gatifloxacin | Pyelonephritis | 11911553;15037328 | 5 |
| Methotrexate | Psoriasis | 20178709;19626273;19323665 | 6 |
| Levofloxacin | Pyelonephritis | without evidence | 7 |
| Cefamandole | Staphylococcal Infections | 9419181 | 8 |
| Cefprozil | Staphylococcal Infections | without evidence | 9 |
| Vinblastine | Kidney Neoplasms | 8602639;11194540 | 10 |
The entries in boldface represent the drug-disease associations supported by recent papers in PubMed but not included in CTD